On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer ...

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology "Scientists can now ...

Genomics is collaborating with PharosAI and leading UK institutions to build a large multimodal cancer dataset using its Xenium spatial platform. The project will use decades of NHS cancer samples to ...

PharosAI brings together King's College London, Queen Mary University of London, Guy's and St Thomas' NHS Foundation Trust and Barts Health NHS Trust in a joint venture that combines clinical ...

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region The Garvan Institute of Medical Research brings together ...

Since the launch of the Hong Kong laboratory in July 2025, Omics Empower has supported research teams with local single-cell sequencing and spatial transcriptomics services. Faster processing helps ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology ...